JP2024503379A - 抗フコシルgm1抗体を使用した組み合わせ療法 - Google Patents

抗フコシルgm1抗体を使用した組み合わせ療法 Download PDF

Info

Publication number
JP2024503379A
JP2024503379A JP2023541613A JP2023541613A JP2024503379A JP 2024503379 A JP2024503379 A JP 2024503379A JP 2023541613 A JP2023541613 A JP 2023541613A JP 2023541613 A JP2023541613 A JP 2023541613A JP 2024503379 A JP2024503379 A JP 2024503379A
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
fucosyl
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503379A5 (cg-RX-API-DMAC7.html
Inventor
リウ,ユー
タネンバウム-ドヴィル,サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024503379A publication Critical patent/JP2024503379A/ja
Publication of JP2024503379A5 publication Critical patent/JP2024503379A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023541613A 2021-01-08 2022-01-07 抗フコシルgm1抗体を使用した組み合わせ療法 Pending JP2024503379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
US63/135,479 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (2)

Publication Number Publication Date
JP2024503379A true JP2024503379A (ja) 2024-01-25
JP2024503379A5 JP2024503379A5 (cg-RX-API-DMAC7.html) 2025-01-08

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541613A Pending JP2024503379A (ja) 2021-01-08 2022-01-07 抗フコシルgm1抗体を使用した組み合わせ療法

Country Status (10)

Country Link
US (1) US20240050564A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274850A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024503379A (cg-RX-API-DMAC7.html)
KR (1) KR20230129467A (cg-RX-API-DMAC7.html)
CN (1) CN116745322A (cg-RX-API-DMAC7.html)
AU (1) AU2022205648A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204392A1 (cg-RX-API-DMAC7.html)
IL (1) IL304200A (cg-RX-API-DMAC7.html)
MX (1) MX2023007780A (cg-RX-API-DMAC7.html)
WO (1) WO2022150557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members
WO2026107143A1 (en) * 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Fixed dose combination of anti-fucosyl-gm1 antibody and anti-pd-1 antibody and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181034A1 (en) * 2016-04-14 2017-10-19 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
WO2019246557A1 (en) * 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP2020515609A (ja) * 2017-03-30 2020-05-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung がんの治療のための抗pd−l1抗体およびdna−pkインヒビターの併用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2017210631A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181034A1 (en) * 2016-04-14 2017-10-19 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
JP2020515609A (ja) * 2017-03-30 2020-05-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung がんの治療のための抗pd−l1抗体およびdna−pkインヒビターの併用
WO2019246557A1 (en) * 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANN ONCOL, vol. Vol. 28, Suppl. 5, JPN6026000269, 2017, pages 539, ISSN: 0005775251 *
CANCER RES, vol. Vol. 76, No. 14, Suppl., JPN6026000270, 2016, ISSN: 0005775252 *
CHIN J CANCER RES, vol. 32, no. 1, JPN6026000273, February 2020 (2020-02-01), pages 115 - 128, ISSN: 0005775255 *
CLIN CANCER RES, vol. 24, no. 20, JPN6026000271, 2018, pages 5178 - 5189, ISSN: 0005775253 *
CLIN TRANSL ONCOL, vol. 21, no. 8, JPN6026000272, 2019, pages 961 - 976, ISSN: 0005775254 *

Also Published As

Publication number Publication date
AU2022205648A9 (en) 2024-09-19
KR20230129467A (ko) 2023-09-08
WO2022150557A1 (en) 2022-07-14
AU2022205648A1 (en) 2023-08-24
MX2023007780A (es) 2023-07-10
CA3204392A1 (en) 2022-07-14
US20240050564A1 (en) 2024-02-15
CN116745322A (zh) 2023-09-12
EP4274850A1 (en) 2023-11-15
IL304200A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
TWI733664B (zh) 包含抗pd1抗體及另一種抗體之組合的組合物
JP7274426B2 (ja) 抗gitrアゴニスト抗体での癌の処置
SG10202111905PA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2020514290A (ja) 標的tgf−β阻害のための投薬計画及び投薬形態
KR20170007750A (ko) Hpv-음성 암의 치료를 위한 pdl-1의 길항제 및 pd-1의 길항제
US11104739B2 (en) Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
JP2022502399A (ja) がんの治療のためのpd−1アンタゴニスト、atrインヒビター、および白金製剤の組合せ
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
US20240050564A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody
KR20240038008A (ko) 암 치료 방법 및 조성물
JP2021523096A (ja) 未治療対象において癌を治療する際に使用するための標的tgf−β阻害のための投与計画
CN111655725A (zh) 用于治疗癌症的组合产品
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
TW202400656A (zh) 使用ctla-4及pd-1雙特異性抗體之治療方法
CN113365659B (zh) 抗pd-l1抗体治疗头颈癌的用途
AU2007299582B2 (en) Anti-cancer antibodies against Lewisy and Lewisb antigens
EA049752B1 (ru) Комбинированная терапия с применением анти-фукозил-gm1 антитела
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
KR20220146488A (ko) 항-cd30 항체-약물 컨쥬게이트 및 비-호지킨 림프종의 치료를 위한 그의 용도
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
AU2024298986C1 (en) Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof
WO2026107143A1 (en) Fixed dose combination of anti-fucosyl-gm1 antibody and anti-pd-1 antibody and uses thereof
TW202515903A (zh) 手術前後基於抗pd-1之治療
TW202517301A (zh) 用b7-h4抗體-藥物結合物治療晚期實體腫瘤之方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260512